Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thalidomide once more in the spotlight].

L T de Jong-van den Berg1, J Rutgers, M C Cornel

  • 1Afd. Sociale Farmacie en Farmaco-epidemiologie, Groninger Institute for Drug Studies, Rijksuniversiteit, Ant., Groningen.

Nederlands Tijdschrift Voor Geneeskunde
|February 24, 1999
PubMed
Summary

Thalidomide, withdrawn due to birth defects, is now approved for erythema nodosum leprosum. Strict safety measures are mandated for its use, including informed consent and contraception.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Detection and treatment of familial hypercholesterolaemia; the earlier, the better?]

Nederlands tijdschrift voor geneeskunde·2020
Same author

Recent developments in genetics and medically-assisted reproduction: from research to clinical applications<sup>†‡</sup>.

Human reproduction open·2019
Same author

Recent developments in genetics and medically assisted reproduction: from research to clinical applications.

European journal of human genetics : EJHG·2017
Same author

Determining the genome-wide kinship coefficient seems unhelpful in distinguishing consanguineous couples with a high versus low risk for adverse reproductive outcome.

BMC medical genetics·2015
Same author

Users evaluate a detailed familial risk questionnaire as valuable and no more time consuming than a simple enquiry in a web-based diabetes risk assessment tool.

Public health·2015
Same author

A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members.

Diabetic medicine : a journal of the British Diabetic Association·2015

Area of Science:

  • Pharmacology
  • Teratology
  • Immunology

Background:

  • Thalidomide was withdrawn globally in the 1960s due to severe teratogenic effects, notably limb reduction defects.
  • Despite its history, thalidomide has demonstrated significant efficacy in treating erythema nodosum leprosum (ENL).

Purpose of the Study:

  • To review the reintroduction and current applications of thalidomide.
  • To outline the safety protocols implemented for thalidomide use.

Main Methods:

  • Review of historical data and regulatory decisions regarding thalidomide.
  • Analysis of clinical findings on thalidomide's efficacy in various conditions.
  • Examination of regulatory requirements for thalidomide prescription and dispensing.

Main Results:

  • Thalidomide is approved for ENL in the United States (since 1997) and has been continuously available in South America for this indication.
  • Efficacy is also noted for other conditions like aphthae and ulcers in AIDS, with ongoing trials for autoimmune diseases.
  • The U.S. Food and Drug Administration (FDA) mandates strict conditions for thalidomide use.

Conclusions:

  • Thalidomide's therapeutic benefits in specific conditions outweigh its historical risks when used under stringent controls.
  • Comprehensive safety measures, including informed consent, contraception, patient education, and monitoring, are crucial for safe thalidomide administration.
  • The re-evaluation and controlled reintroduction of thalidomide highlight its importance in managing certain debilitating diseases.

Related Experiment Videos